Cover Image
close this bookPost-Durban Update on ARVs for MTCT-prevention (UNAIDS, 2000, 8 p.)
View the document(introduction...)
View the documentShort term efficacy (6 weeks to 3 months)
View the documentLong-term efficacy (12 to 24 months)
View the documentARV and transmission through breast feeding
View the documentDrug resistance with Nevirapine
View the documentConclusion
View the documentReferences

(introduction...)

Tim Farley,a Dirk Buyse and Philippe Gaillard
Department of Reproductive Health and Research
World Health Organization, Geneva, Switzerland
and Jos Perriens
and Department of Policy, Strategy and Research, UNAIDS, Geneva, Switzerland

a Tel: +41 22 791 33 10, fax: +41 22 791 41 71, email: farleyt@who.int

At the 13th AIDS Conference in Durban new data from the following randomized clinical trials on the use of antiretrovirals (ARVs) to prevent mother to child transmission were presented:

· PETRA Trial (South Africa, Tanzania and Uganda)

· Perinatal HIV Prevention Trial (Thailand)

· ANRS/CDC pooled analysis - West Africa (Cd’Ivoire and Burkina Faso)

· SAINT Study (South Africa)

· HIVNET012 trial (Uganda)

· BMS AI455-094 (South Africa).

Observational data from the USA addressed the efficacy and safety of combination ARVs. The attached tables summarize these new results together with the previously available results.